Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells

Cancer Letters

Volumn 294, Issue 2, 2010, Pages 167-177

  Jing, Hui ^a   Zhou, Xinglu ^a   Dong, Xiaowu ^a   Cao, Ji ^a   Zhu, Hong ^a   Lou, Jianshu ^a   Hu, Yongzhou ^a   He, Qiaojun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Akt; Anti proliferative effect; Chemotherapy; Computational simulation; Isobavachalcone

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; ISOBAVACHALCONE; PROCASPASE 3; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; INSULIN RELEASE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; CASPASES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CHALCONES; CYTOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MALE; MICE; MITOCHONDRIA; MODELS, MOLECULAR; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 77953356093     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.035     Document Type: Article

References (56)

1. Vivanco I., Sawyers C.L. Review: the phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
2. Luo J., Manning B.D., Cantley L.C. Review: targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 2003, 4:257-262.
3. Bellacosa A., Testa J.R., Staal S.P., Tsichlis P.N. A retroviral oncogene, Akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991, 254:274-277.
4. Coffer P.J., Woodgett J.R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. 1991, 201:475-481.
5. Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc. Natl. Acad. Sci. USA 1991, 88:4171-4175.
6. Franke T.F., Kaplan D.R., Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88:435-437.
7. Kulik G., Klippel A., Weber M.J. Antiapoptotic signalling by the insulin like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 1997, 17:1595-1606.
8. Delcommenne M., Tan C., Gray V., Rue L., Woodgett J., Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. USA 1998, 95:11211-11216.
9. Sharma M., Chuang W.W., Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J. Biol. Chem. 2002, 277:30935-30941.
10. Calleja V., Alcor D., Laguerre M., Park J., Vojnovic B., Hemmings B.A., Downward J., Parker P.J., Larijani B. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol. 2007, 5:780-791.
11. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 1997, 7:261-269.
12. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 2005, 307:1098-1101.
13. Lawlor M.A., Alessi D.R. Review: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J. Cell. Sci. 2004, 114:2903-2910.
14. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H.M., Cinalli R.M., Alavi A., Rudin C.M., Thompson C.B. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004, 64:3892-3899.
15. Lim K.H., Counter C.M. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005, 8:381-392.
16. Clark A.S., West K., Streicher S., Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002, 1:707-717.
17. Brognard J., Clark A.S., Ni Y., Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61:3986-3997.
18. Granville C.A., Memmott R.M., Gills J.J., Dennis P.A. Review: handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 2006, 12:679-689.
19. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Review: exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
20. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 2006, 441:424-430.
21. Mann J. Review: natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer 2002, 2:143-148.
22. Cragg G.M., Newman D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005, 100:72-79.
23. Zhao L.H., Huang C.Y., Shan Z., Xiang B.G., Mei L.H. Fingerprint analysis of Psoralea corylifolia L. by HPLC and LC-MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 821:64-67.
24. Nakata K., Taniguchi M., Baba K. Three Chalcones from Angelica keiskei. Nat. Med. 1999, 53:329-332.
25. Lee D., Bhat K.P.L., Fong H.H.S., Farnsworth N.R., Pezzuto J.M., Kinghorn A.D. Aromatase inhibitors from Broussonetia papyrifera. J. Nat. Prod. 2001, 64:1286-1293.
26. Akihisa T., Tokuda H., Hasegawa D., Ukiya M., Kimura Y., Enjo F., Suzuki T., Nishino H. Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. J. Nat. Prod. 2006, 69:38-42.
27. Nishimura R., Tabata K., Arakawa M., Ito Y., Kimura Y., Akihisa T., Nagai H., Sakuma A., Kohno H., Suzuki T. Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Bio. Pharm. Bull. 2007, 30:1878-1883.
28. Ling Y., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. 2003, 278:33714-33723.
29. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., Nicosia S.V. Review: The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005, 24:7482-7492.
30. Sybyl6.9. Molecular Modelling System. Tripos Associates, St. Louis, MO, USA.
31. Cao J., Xu D., Wang D., Wu R., Zhang L., Zhu H., He Q., Yang B. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic. Biol. Med. 2009, 47:536-547.
32. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 1992, 89:9267-9271.
33. Vlietstra R.J., Van Alewijk D.C., Hermans K.G., van Steenbrugge G.J., Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998, 58:2720-2723.
34. Toral-Barza L., Zhang W.G., Huang X., McDonald L.A., Salaski E.J., Barbieri L.R., Ding W., Krishnamurthy G., Hu Y.B., Lucas J., Bernan V.S., Cai P., Levin J.I., Mansour T.S., Gibbons J.J., Abraham R.T., Yu K. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol. Cancer Ther. 2007, 6:3028-3038.
35. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., Hamilton A.D., Polokoff M., Nicosia S.V., Herlyn M., Sebti S.M., Cheng J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004, 64:4394-4399.
36. Obata T., Yaffe M.B., Leparc G.G., Piro E.T., Maegawa H., Kashiwagi A., Kikkawa R., Cantley L.C. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J. Biol. Chem. 2000, 275:36108-36115.
37. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15:6541-6551.
38. Guo S.D., Rena G., Cichy S., He X.W., Cohen P., Unterman T. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J. Biol. Chem. 1999, 274:17184-17192.
39. Brownawell A.M., Kops G.J.P.L., Macara I.G., Burgering B.M.T. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol. Cell. Biol. 2001, 21:3534-3546.
40. Cross D., Alessi D., Cohen P., Andjelkovich M., Hemmings B. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
41. Rhodes N., Heerding D.A., Duckett D.R., Eberwein D.J., Knick V.B., Lansing T.J., McConnell R.T., Gilmer T.M., Zhang S.Y., Robell K., Kahana J.A., Geske R.S., Kleymenova E.V., Choudhry A.E., Lai Z., Leber J.D., Minthorn E.A., Strum S.L., Wood E.R., Huang P.S., Copeland R.A., Kumar R. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 2008, 68:2366-2374.
42. Datta S.R., Dudek H., Tao X., Masters S., Fu H.A., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
43. del Peso L., Gonzalez-Garcia M., Page C., Herrera R., Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689.
44. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., Masuyama N., Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 2002, 277:21843-21850.
45. Feng J.H., Tamaskovic R., Yang Z.Z., Brazil D.P., Merlo A., Hess D., Hemmings B.A. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J. Biol. Chem. 2004, 279:35510-35517.
46. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., Tsang B.K., Cheng J.Q. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 2004, 279:5405-5412.
47. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 28:1322-1326.
48. Garcia-Echeverria C., Sellers W.R. Review: drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
49. Bailly C. Review: ready for a comeback of natural products in oncology. Biochem. Pharmacol. 2009, 77:1447-1457.
50. Rollinger J.M. Accessing target information by virtual parallel screening - the impact on natural product research. Phytochem. Lett. 2009, 2:53-58.
51. Hirano I., Nakamura S., Yokota D., Ono T., Shigeno K., Fujisawa S., Shinjo K., Ohnishir K. Depletion of pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms. J. Biol. Chem. 2009, 284:22155-22165.
52. Luo Y., Shoemaker A.R., Liu XS W.K., Thomas S.A., de Jong R., Han E.K., Li T.M., Stoll V.S., Powlas J.A., Oleksijew A., Mitten M.J., Shi Y., Guan R., McGonigal T.P., Klinghofer V., Johnson E.F., Leverson J.D., Bouska J.J., Mamo M., Smith R.A., Gramling-Evans E.E., Zinker B.A., Mika A.K., Nguyen P.T., Oltersdorf T., Rosenberg S.H., Li Q., Giranda V.L. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol. Cancer Ther. 2005, 4:977-986.
53. Okuzumi T., Fiedler D., Zhang C., Gray D.C., Aizenstein B., Hoffman R., Shokat K.M. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 2009, 5:484-493.
54. Zhang C., Yang N., Yang C.H., Ding H.S., Luo C., Zhang Y., Wu M.J., Zhang X.W., Shen X., Jiang H.L., Meng L.H., Ding J. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One 2009, 4:e4881.
55. Miyamoto S., Rubio M., Sussman M.A. Review: nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc. Res. 2009, 82:272-285.
56. Castillo S.S., Brognard J., Petukhov P.A., Zhang C., Tsurutani J., Granville C.A., Li M., Jung M., West K.A., Gills J.G., Kozikowski A.P., Dennis P.A. Preferential inhibition of Akt, killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res. 2004, 64:2782-2792.